110 related articles for article (PubMed ID: 14531831)
21. Fatal fulminant hepatic failure associated with benzbromarone.
Wagayama H; Shiraki K; Sugimoto K; Fujikawa K; Shimizu A; Takase K; Nakano T; Tameda Y
J Hepatol; 2000 May; 32(5):874. PubMed ID: 10845680
[No Abstract] [Full Text] [Related]
22. Uricosuric effect of irtemazole in hyperuricemic patients without and with renal insufficiency.
Kamilli I; Gresser U; Pellkofer T; Löffler W; Zöllner N
Z Rheumatol; 1989; 48(6):307-12. PubMed ID: 2623976
[TBL] [Abstract][Full Text] [Related]
23. [Familial juvenile hyperuricemic nephropathy].
Yamaoka T
Nihon Rinsho; 2003 Jan; 61 Suppl 1():273-7. PubMed ID: 12629730
[No Abstract] [Full Text] [Related]
24. Fulminant hepatic failure associated with benzbromarone treatment: a case report.
Arai M; Yokosuka O; Fujiwara K; Kojima H; Kanda T; Hirasawa H; Saisho H
J Gastroenterol Hepatol; 2002 May; 17(5):625-6. PubMed ID: 12084041
[No Abstract] [Full Text] [Related]
25. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
26. Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice.
Wang CP; Wang Y; Wang X; Zhang X; Ye JF; Hu LS; Kong LD
Planta Med; 2011 May; 77(8):786-94. PubMed ID: 21154198
[TBL] [Abstract][Full Text] [Related]
27. Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice.
Hua J; Huang P; Zhu CM; Yuan X; Yu CH
J Ethnopharmacol; 2012 Jun; 142(1):248-52. PubMed ID: 22575704
[TBL] [Abstract][Full Text] [Related]
28. [Renal affection in gout].
Egorov IV; Tsurko VV
Ter Arkh; 2012; 84(1):65-8. PubMed ID: 22616535
[TBL] [Abstract][Full Text] [Related]
29. [Hyperuricemia and the kidney].
Reutter F
ZFA (Stuttgart); 1976 Feb; 52(4):193-6. PubMed ID: 1266328
[No Abstract] [Full Text] [Related]
30. [Analysis of the hypo-uricemic action of benzbromarone in 40 cases of gouty and non-gouty hyperuricemia].
Famaey JP; Vandenabeele G
J Belge Rhumatol Med Phys; 1970; 25(1):5-9. PubMed ID: 5486285
[No Abstract] [Full Text] [Related]
31. Anti-hyperuricemic and nephroprotective effects of rhein in hyperuricemic mice.
Meng Z; Yan Y; Tang Z; Guo C; Li N; Huang W; Ding G; Wang Z; Xiao W; Yang Z
Planta Med; 2015 Mar; 81(4):279-85. PubMed ID: 25760382
[TBL] [Abstract][Full Text] [Related]
32. [Gout].
Gröbner W; Zöllner N
Z Rheumatol; 2004 Feb; 63(1):2-9. PubMed ID: 14991273
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of anticoagulant action by warfarin-benzbromarone interaction.
Shimodaira H; Takahashi K; Kano K; Matsumoto Y; Uchida Y; Kudo T
J Clin Pharmacol; 1996 Feb; 36(2):168-74. PubMed ID: 8852393
[TBL] [Abstract][Full Text] [Related]
34. Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment.
Kadowaki D; Sakaguchi S; Miyamoto Y; Taguchi K; Muraya N; Narita Y; Sato K; Chuang VT; Maruyama T; Otagiri M; Hirata S
Biol Pharm Bull; 2015; 38(3):487-92. PubMed ID: 25757933
[TBL] [Abstract][Full Text] [Related]
35. [Chronic gout. Case report of a severe course of disease].
Boxberger F; Harsch IA; Brueckl WM; Hautmann M; Baum U; Hahn EG; Wein A
Med Klin (Munich); 2003 Nov; 98(11):646-7. PubMed ID: 14631540
[No Abstract] [Full Text] [Related]
36. Bibliography. Current world literature. Crystal deposition disease.
Curr Opin Rheumatol; 2008 Mar; 20(2):226-31. PubMed ID: 18357635
[No Abstract] [Full Text] [Related]
37. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Hanvivadhanakul P; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
[TBL] [Abstract][Full Text] [Related]
38. [Therapy of gouty nephropathy].
Mertz DP
Minerva Med; 1973 Aug; 64(58):3055-7. PubMed ID: 4742645
[No Abstract] [Full Text] [Related]
39. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
40. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
